Elevated circulating unsaturated fatty acids: A novel metabolic feature of coronary artery disease without

Zijian Wang1,2, Xue Li2,3, Tao Hu2

  • 1Department of Cardiology, Affiliated Hospital of Southwest Medical University, Luzhou, People's Republic of China.

Insights

Coronary artery disease (CAD) patients without traditional risk factors show altered unsaturated fatty acid (UFA) metabolism. Elevated UFAs may serve as novel biomarkers for predicting CAD risk in this population.

Area of Science:

  • Metabolomics
  • Biochemistry
  • Cardiovascular Disease Research

Background:

  • Coronary artery disease (CAD) is a leading global cause of death.
  • Many CAD patients lack conventional risk factors, indicating a residual risk.
  • Identifying novel biomarkers for this subgroup is crucial for prevention.

Purpose of the Study:

  • To investigate potential metabolomic biomarkers for residual risk in CAD patients without traditional risk factors.
  • To explore the role of dysregulated metabolism in CAD pathogenesis in this specific population.

Main Methods:

  • Untargeted metabolomic profiling of serum using ultra-high-performance liquid chromatography-tandem mass spectrometry (UHPLC-MS/MS).
  • Comparative analysis between CAD patients lacking conventional risk factors and non-CAD controls.
  • Pathway analysis to identify enriched metabolic pathways.

Main Results:

  • Significant alterations in metabolite levels were observed in CAD patients.
  • 43 metabolites were elevated and 46 were reduced compared to controls.
  • A marked upregulation of circulating unsaturated fatty acids (UFAs) was identified, suggesting dysregulated UFA biosynthesis.

Conclusions:

  • Dysregulated unsaturated fatty acid metabolism may play a role in CAD pathogenesis.
  • Elevated circulating UFAs represent a novel metabolic signature in CAD patients without conventional risk factors.
  • These UFAs could serve as potential predictive biomarkers for noninvasive risk stratification and targeted prevention, requiring further validation.

Related Concept Videos

Coronary Artery Disease II: Pathophysiology01:26

Coronary Artery Disease II: Pathophysiology

Coronary Artery Disease (CAD) originates from a series of events that impair the function of coronary arteries, the blood vessels responsible for delivering oxygen-rich blood to the heart muscle. The pathophysiology of CAD is closely linked to atherosclerosis, a chronic inflammatory and lipid-driven condition affecting the vascular endothelium.1. Endothelial DamageThe process begins with damage to the vascular endothelium, which serves as a protective barrier between the blood and the vessel...
1.0K
Coronary Artery Disease I: Introduction01:30

Coronary Artery Disease I: Introduction

Coronary Artery Disease (CAD): An Overview with Scientific InsightsCoronary Artery Disease (CAD), often referred to as C-A-D, is a prevalent blood vessel disorder classified under the broader category of atherosclerosis. Atherosclerosis is a pathological process characterized by the hardening and narrowing of arteries due to the accumulation of atherosclerotic plaques. These plaques are composed of cholesterol, fatty substances, inflammatory cells, calcium, and fibrin, reducing blood flow to...
1.7K
Coronary Artery Disease IV: Preventive Measures01:26

Coronary Artery Disease IV: Preventive Measures

Effective preventive measures for coronary artery disease (CAD) focus on controlling modifiable risk factors, including cholesterol abnormalities and lifestyle changes.Cholesterol ManagementFirst, the Mediterranean diet and the American Heart Association advocate for maintaining low-density lipoprotein (LDL) cholesterol levels below 100 mg/dL, with a more stringent recommendation of below 70 mg/dL for individuals at high risk. LDL cholesterol, often termed "bad cholesterol," can lead to the...
863
Atherosclerosis III: Management01:26

Atherosclerosis III: Management

Management of atherosclerosis involves an integrated strategy encompassing pharmacological treatment, surgical interventions, lifestyle changes, and nutrition therapy to address the multifactorial nature of the disease.Pharmacological TherapyA cornerstone of atherosclerosis management is the use of pharmacological agents. Statins, such as atorvastatin, are pivotal in inhibiting HMG-CoA reductase, an enzyme that catalyzes an initial step in cholesterol synthesis in the liver. This reduction in...
593
Peripheral Artery Disease I: Introduction01:30

Peripheral Artery Disease I: Introduction

Peripheral artery disease (PAD) predominantly results from atherosclerosis, which involves the accumulation of fatty deposits, or plaques, within the walls of arteries. This causes them to narrow and harden, significantly reducing blood flow. PAD predominantly affects the legs, particularly the arteries supplying the thighs and calves. In rare cases, it may involve other arteries, including those in the arms.Etiology of PAD:The principal cause of PAD is atherosclerosis, which results from fatty...
639
Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations01:19

Acute Coronary Syndrome II: Pathophysiology and Clinical Manifestations

The pathophysiology of Acute Coronary Syndrome [ACD] involves several key processes:The main underlying cause of ACD is atherosclerosis, a chronic inflammatory disease characterized by the buildup of lipid-laden plaques within the coronary arteries.As the atherosclerotic plaque grows in the coronary artery, it may become unstable due to the formation of a lipid-rich core and a thin fibrous cap. Inflammatory cells within the plaque, such as macrophages, secrete enzymes that degrade the...
778